article thumbnail

Atherosclerotic plaque stabilization and regression: a review of clinical evidence

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 04 January 2024; doi:10.1038/s41569-023-00979-8 In this Review, Sarraju and Nissen summarize the clinical trial evidence for coronary atherosclerotic plaque stabilization and regression with plasma LDL-cholesterol-lowering therapy and other treatments.

Plaque 139
article thumbnail

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

DAIC

mtaschetta-millane Thu, 07/18/2024 - 10:00 July 18, 2024 — HeartFlow, Inc. , a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. medical director of CV imaging, nuclear and CT, Charleston, WV. F.A.C.C.

article thumbnail

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

DAIC

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104
article thumbnail

Fibroblast-like cells promote plaque stability in response to anti-IL-1? therapy

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 23 January 2024; doi:10.1038/s41569-024-00993-4 Anti-inflammatory therapy involving IL-1β inhibition might reduce the risk of cardiovascular events in individuals with clonal haematopoiesis by increasing the number of fibroblast-like cells in the fibrous cap region of atherosclerotic plaques, thereby stabilizing (..)

Plaque 78
article thumbnail

Long-Term Safety Data Highlight Potential of Bimekizumab in Plaque Psoriasis

HCPLive

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

Plaque 59
article thumbnail

Abbott Enters IVL Burgeoning Segment

CardiacWire

IVL is a minimally invasive medical catheter-based procedure that treats calcified plaque in blood vessels. Notably, FastWaves FIH trial was successful last year, while Amplitudes Pulse IVL system secured its IDE approval in June of 2024.

Plaque 59
article thumbnail

Cardiology in H1 2024

CardiacWire

The first half of 2024 is now a wrap, and it was another big one in cardiology. Pulsed Field Awakening – Pulsed field ablation was the clear electrophysiology highlight of 2024 so far, after dominating conversations at HRS 2024 , producing mounting evidence of its advantages, and scoring its first FDA approval.